A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)

Inclusion Criteria: * Participants aged 18 and above. * Diagnosis of rheumatoid arthritis (RA) for ≥ 3 months. * ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and baseline visit. * Erythrocyte sedimentation rate (ESR) ≥ 28mm/h or high-sensitivity C-Reactive Protein (hsCRP) ≥ ULN at Screening. * Participants have been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug. * Have an inadequate response to ≥ 1 bDMARD. Exclusion Criteria: * Subjects who were prior exposure to Janus Kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib) and have evidence showing an inadequate response or intolerance. * Subjects who received intra-articular, intramuscular, intravenous, trigger point or tender point, intracapsular, or intra-tendon injections of glucocorticoids within 4 weeks before randomization. * Current diagnosis of systemic inflammatory disease other than RA. * History of malignancy or current diagnosis of malignancy within 5 years before screening visit. * Uncontrolled diabetes, hypertension, kidney disease, liver disease, severe heart disease.